---
authors: Fisher JL, Wilk EJ, Oza VH, Gary SE, Howton TC, Flanary VL, Clark AD, Hjelmeland
  AB, Lasseigne BN
carousel: false
doi: 10.1002/2211-5463.13796
featured: false
issue: '5'
journal: FEBS open bio
keywords: '["Gene Expression Profiling", "cancer", "Drug Repositioning", "glioblastoma",
  "Animals", "Glioblastoma", "Gene Expression Regulation, Neoplastic", "gene signature",
  "Mice", "Brain Neoplasms", "transcriptomic signature", "Xenograft Model Antitumor
  Assays", "Transcriptome", "Antineoplastic Agents", "Neoplasms", "Cell Line, Tumor",
  "drug repurposing", "Humans"]'
landmark: false
layout: ../../layouts/Publication.astro
page: 803-830
pmcid: PMC11073506
pmid: 38531616
r03: R03OD030604
title: Signature reversion of three disease-associated gene signatures prioritizes
  cancer drug repurposing candidates.
volume: '14'
year: 2024

---